Novartis Reports Results of QMF149 (indacaterol acetate and mometasone furoate) in P-III QUARTZ Study for Inadequately Controlled Asthma

 Novartis Reports Results of QMF149 (indacaterol acetate and mometasone furoate) in P-III QUARTZ Study for Inadequately Controlled Asthma

Novartis Reports Results of QMF149 (indacaterol acetate and mometasone furoate) in P-III QUARTZ Study for Inadequately Controlled Asthma

Shots:

  • The P-III QUARTZ study results involves assessing of QMF149 (150/80 Mu g) vs mometasone furoate (200 Mu g) delivered via Breezhaler & Twisthaler in 802 adult and adolescent patients in a ratio (1:1) with inadequately controlled asthma respectively
  • The P-III QUARTZ study results: @12wks. met its 1EPs & 2EPs; improvement in lung function; improvements in evening PEF (26.1 L/min); improvements in asthma control as measured by ACQ-7 (74.7% vs 64.9%); AEs (32.3% vs 38.3%)
  • QMF149 (qd) is an inhaled fixed-dose combination therapy delivered with the dose-confirming Breezhaler device and is evaluated under Novartis’ P-III PLATINUM Program. Novartis enters into an exclusive license agreement with Merck for mometasone furoate to use in QMF149 candidate

Click here to read full press release/ article | Ref: Novartis | Image: Pinterest

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post